AKT1 and prostate carcinoma: Mechanistically, the ubiquitination level of c-MYC was reduced (Figure 5F) and degradation of c-MYC was attenuated (Figure 5G) by the activation of Akt in SIRT3 overexpressed prostate cancer cells.